

94. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA Jr, Criner GJ, Curtis JL, Dransfield MT, Han MK, Lazarus SC, Make B, Marchetti N, Martinez FJ, Madinger NE, McEvoy C, Niewoehner DE, Porsasz J, Price CS, Reilly J, Scanlon PD, Sciurba FC, Scharf SM, Washko GR, Woodruff PG, Anthonisen NR; COPD Clinical Research Network. Azithromycin for prevention of exacerbations of COPD. *N Engl J Med*. 2011; 365:689-98.
95. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. *N Engl J Med*. 2012; 366:1881-90.
96. Serisier DJ. Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. *Lancet Respir Med*. 2013; 1:262-74.
97. Isada CM, Stoller JK. Chronic bronchitis: the role of antibiotics. In: Niederman MS, Sarosi GA, Glassroth J, eds. *Respiratory infections: a scientific basis for management*. London: WB Saunders; 1994.
98. Siafakas NM, Celli BR. Overall management of stable chronic obstructive Pulmonary disease. In: *Management of Chronic Obstructive Pulmonary Disease* Edited by N.M. Siafakas. *Eur Respir Mon*. 2006; 38:258-265.
99. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ ERS position paper. *Eur Respir J*. 2004; 23:932-46.
100. Irwin RS, Boulet LP, Cloutier MM, Fuller R, Gold PM, Hoffstein V, Ing AJ, McCool FD, O'Byrne P, Poe RH, Prakash UB, Pratter MR, Rubin BK. Managing cough as a defense mechanism and as a symptom. A consensus panel report of the American College of Chest Physicians. *Chest*. 1998; 114:133-81.
101. Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. *Lancet*. 1999; 354:456-60.
102. Maltais F, Ostinelli J, Bourbeau J, Tonnel AB, Jacquemet N, Haddon J, Rouleau M, Boukhana M, Martinot JB, Duroux P. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. *Am J Respir Crit Care Med*. 2002; 165:698-703.
103. Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, Anderson P, Morgan NA. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. *N Engl J Med*. 1999; 340:1941-7.



Με την συγχρηματοδότηση
της Ελλάδας και της
Ευρωπαϊκής Ένωσης



www.espa.gr

www.ygeia-pronoia.gr

104. Thompson WH, Nielson CP, Carvalho P, Charan NB, Crowley JJ. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. *Am J Respir Crit Care Med.* 1996; 154:407-12.
105. Alía I, de la Cal MA, Esteban A, Abella A, Ferrer R, Molina FJ, Torres A, Gordo F, Elizalde JJ, de Pablo R, Huete A, Anzueto A. Efficacy of corticosteroid therapy in patients with an acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory support. *Arch Intern Med.* 2011; 171(21):1939-46.
106. Aaron SD, Vandemheen KL, Hebert P, Dales R, Stiell IG, Ahuja J, Dickinson G, Brison R, Rowe BH, Dreyer J, Yetisir E, Cass D, Wells G. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. *N Engl J Med.* 2003; 348:2618-25.
107. Walters JA, Wang W, Morley C, Soltani A, Wood-Baker R. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. *Cochrane Database Syst Rev.* 2011; (10):CD006897.
108. Ram FS, Rodriguez-Roisin R, Granados-Navarrete A, Garcia-Aymerich J, Barnes NC. Antibiotics for exacerbations of chronic obstructive pulmonary disease. *Cochrane Database Syst Rev.* 2006; (2):CD004403.
109. Nouira S, Marghli S, Belghith M, Besbes L, Elatrous S, Abroug F. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial. *Lancet.* 2001; 358:2020-5.
110. Barbera JA, Reyes A, Roca J, Montserrat JM, Wagner PD, Rodriguez-Roisin R. Effect of intravenously administered aminophylline on ventilation/perfusion inequality during recovery from exacerbations of chronic obstructive pulmonary disease. *Am Rev Respir Dis.* 1992; 145:1328-33.
111. Lloberes P, Ramis L, Montserrat JM, Serra J, Campistol J, Picado C, Agusti-Vidal A. Effect of three different bronchodilators during an exacerbation of chronic obstructive pulmonary disease. *Eur Respir J.* 1988; 1:536-9.
112. Mahon JL, Laupacis A, Hodder RV, McKim DA, Paterson NA, Wood TE, Donner A. Theophylline for irreversible chronic airflow limitation: a randomized study comparing n of 1 trials to standard practice. *Chest.* 1999; 115:38-48.



Με την συγχρηματοδότηση
της Ελλάδας και της
Ευρωπαϊκής Ένωσης



www.espa.gr

www.ygeia-pronoia.gr

113. Murciano D, Aubier M, Lecocguic Y, Pariente R. Effects of theophylline on diaphragmatic strength and fatigue in patients with chronic obstructive pulmonary disease. *N Engl J Med.* 1984; 311:349-53.

114. Barr RG, Rowe BH, Camargo CA, Jr. Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials. *BMJ.* 2003; 327(7416):643.

115. Duffy N, Walker P, Diamantea F, Calverley PM, Davies L. Intravenous aminophylline in patients admitted to hospital with non-acidotic exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. *Thorax.* 2005; 60:713-7.

116. Lightowler JV, Wedzicha JA, Elliott MW, Ram FS. Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. *BMJ.* 2003; 326(7382):185.

117. Esteban A, Anzueto A, Alia I, Gordo F, Apezteguía C, Pálizas F, Cide D, Goldwaser R, Soto L, Bugedo G, Rodrigo C, Pimentel J, Raimondi G, Tobin MJ. How is mechanical ventilation employed in the intensive care unit? An international utilization review. *Am J Respir Crit Care Med.* 2000; 161:1450-8.

118. The American Thoracic Society, the European Respiratory Society, the European Society of Intensive Care Medicine, and the Société de Réanimation de Langue Française, approved by ATS Board of Directors. International Consensus Conferences in Intensive Care Medicine: noninvasive positive pressure ventilation in acute respiratory failure. *Am J Respir Crit Care Med.* 2001; 163(1):283-91.

119. Connors AF, Jr, Dawson NV, Thomas C, Harrell FE Jr, Desbiens N, Fulkerson WJ, Kussin P, Bellamy P, Goldman L, Knaus WA. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). *Am J Respir Crit Care Med.* 1996; 154:959-67.

120. Gravit JH, Al-Rawas OA, Cotton MM, Flanigan U, Irwin A, Stevenson RD. Home treatment of exacerbations of chronic obstructive pulmonary disease by an acute respiratory assessment service. *Lancet.* 1998; 351:1853-5.



ΕΥΡΩΠΑΪΚΗ ΕΝΩΣΗ



www.ygeia-pronoia.gr

Με την συγχρηματοδότηση
της Ελλάδας και της
Ευρωπαϊκής Ένωσης



www.espa.gr

121. Bahadori K, FitzGerald JM. Risk factors of hospitalization and readmission of patients with COPD exacerbation-systematic review. *Int J Chron Obstruct Pulmon Dis.* 2007; 2:241-51.
122. Cotton MM, Bucknall CE, Dagg KD, Johnson MK, MacGregor G, Stewart C, Stevenson RD. Early discharge for patients with exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. *Thorax.* 2000; 55:902-6.
123. Hermiz O, Comino E, Marks G, Daffurn K, Wilson S, Harris M. Randomised controlled trial of home based care of patients with chronic obstructive pulmonary disease. *BMJ.* 2002; 325:938.
124. Jeppesen E, Brurberg KG, Vist GE, Wedzicha JA, Wright JJ, Greenstone M, Walters JA. Hospital at home for acute exacerbations of chronic obstructive pulmonary disease. *Cochrane Database Syst Rev.* 2012; (5):CD003573.
125. Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. *Chest.* 2005; 128(4):2099-107.
126. Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA, MacNee W, Miller BE, Rennard S, Silverman EK, Tal-Singer R, Wouters E, Yates JC, Vestbo J; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators. Characterisation of COPD heterogeneity in the ECLIPSE cohort. *Respir Res.* 2010; 11:122.
127. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. *Eur Respir J.* 2008; 32:962-9.
128. Johnston AK, Mannino DM, Hagan GW, Davis KJ, Kiri VA. Relationship between lung function impairment and incidence or recurrence of cardiovascular events in a middle-aged cohort. *Thorax.* 2008; 63:599-605.
129. Lange P, Mogelvang R, Marott JL, Vestbo J, Jensen JS. Cardiovascular morbidity in COPD: A study of the general population. *COPD.* 2010; 7(1):5-10.
130. Rutten FH, Cramer MJ, Grobbee DE, Sachs AP, Kirkels JH, Lammers JW, Hoes AW. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. *Eur Heart J.* 2005; 26:1887-94.



ΕΥΡΩΠΑΪΚΗ ΕΝΩΣΗ



www.ygeia-pronoia.gr

Με την συγχρηματοδότηση
της Ελλάδας και της
Ευρωπαϊκής Ένωσης



www.espa.gr

131. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane database of systematic reviews. 2005; (4):CD003566.
132. Mainguy V, Girard D, Maltais F, Saey D, Milot J, Sénéchal M, Poirier P, Provencher S. Effect of bisoprolol on respiratory function and exercise capacity in chronic obstructive pulmonary disease. *Am J Cardiol.* 2012; 110(2):258-63.
133. Hawkins NM, Jhund PS, Simpson CR, Petrie MC, Macdonald MR, Dunn FG, Macintyre K, McMurray JJ. Primary care burden and treatment of patients with heart failure and chronic obstructive pulmonary disease in Scotland. *Eur J Heart Fail.* 2010; 12:17-24.
134. Hawkins NM, MacDonald MR, Petrie MC, Chalmers GW, Carter R, Dunn FG, McMurray JJ. Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. *Eur J Heart Fail.* 2009; 11:684-90.
135. Jabbour A, Macdonald PS, Keogh AM, Kotlyar E, Mellemkjaer S, Coleman CF, Elsik M, Krum H, Hayward CS. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. *J Am Coll Cardiol.* 2010; 55:1780-7.
136. Fabbri LM, Luppi F, Beghe B, Rabe KF. Complex chronic comorbidities of COPD. *Eur Respir J.* 2008; 31:204-12.
137. Madsen H, Brixen K, Hallas J. Screening, prevention and treatment of osteoporosis in patients with chronic obstructive pulmonary disease - a population-based database study. *Clin Respir J.* 2010; 4:22-9.
138. Connors GL, Hilling L; American Association of Cardiovascular & Pulmonary Rehabilitation. Guidelines for pulmonary rehabilitation programs / American Association of Cardiovascular and Pulmonary Rehabilitation. Champaign, IL: Human Kinetics Press; 1993.
139. Royal College of Physicians. Osteoporosis: clinical guidelines for the prevention and treatment. London: Royal College of Physicians; 1999.
140. Tsiligianni IG, Kosmas E, van der Molen T, Tzanakis N. Managing Comorbidity in COPD: A Difficult Task. *Curr Drug Targets.* 2013; 14(2):158-76.



ΕΥΡΩΠΑΪΚΗ ΕΝΩΣΗ



www.ygeia-pronoia.gr

Με την συγχρηματοδότηση
της Ελλάδας και της
Ευρωπαϊκής Ένωσης

2007-2013

Ε.Π.
ΔΙΟΙΚΗΤΙΚΗ
ΜΕΤΑΡΡΥΘΜΙΣΗ
ΜΕΣΤΡΩΣΕΩΝ



www.espa.gr

141. Lehouck A, Boonen S, Decramer M, Janssens W. COPD, bone metabolism, and osteoporosis. *Chest*. 2011; 139(3):648-57.
142. Hanania NA, Mullerova H, Locantore NW, Vestbo J, Watkins ML, Wouters EF, Rennard SI, Sharafkhaneh A; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study investigators. Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. *Am J Respir Crit Care Med*. 2011; 183:604-11.
143. Kunik ME, Roundy K, Veazey C, Soucek J, Richardson P, Wray NP, Stanley MA. Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. *Chest*. 2005; 127:1205-11.
144. Ng TP, Niti M, Tan WC, Cao Z, Ong KC, Eng P. Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. *Arch Intern Med*. 2007; 167:60-7.
145. Maurer J, Rebbapragada V, Borson S, Goldstein R, Kunik ME, Yohannes AM, Hanania NA; ACCP Workshop Panel on Anxiety and Depression in COPD. Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. *Chest*. 2008; 134:43-56.
146. Cleland JA, Lee AJ, Hall S. Associations of depression and anxiety with gender, age, health-related quality of life and symptoms in primary care COPD patients. *Fam Pract*. 2007; 24(3):217-23.
147. Van Manen JG, Bindels PJ, Dekker FW, IJzermans CJ, van der Zee JS, Schadé E. Risk of depression in patients with chronic obstructive pulmonary disease and its determinants. *Thorax*. 2002; 57(5):412-16.
148. Stoller JK, Panos RJ, Krachman S, Doherty DE, Make B. Oxygen therapy for patients with COPD: current evidence and the long-term oxygen treatment trial. *Chest*. 2010; 138:179-87.
149. Ahmedzai S, Balfour-Lynn IM, Bewick T, Buchdahl R, Coker RK, Cummin AR, Gradwell DP, Howard L, Innes JA, Johnson AO, Lim E, Lim WS, McKinlay KP, Partridge MR, Popplestone M, Pozniak A, Robson A, Shovlin CL, Shrikrishna D, Simonds A, Tait P, Thomas M; British Thoracic Society Standards of Care Committee. Managing passengers with stable respiratory



ΕΥΡΩΠΑΪΚΗ ΕΝΩΣΗ



www.ygeia-pronoia.gr

Με την συγχρηματοδότηση
της Ελλάδας και της
Ευρωπαϊκής Ένωσης



Ε.Π.
ΔΙΟΙΚΗΤΙΚΗ
ΜΕΤΑΡΡΥΘΜΙΣΗ
ΜΕΛΕΤΕΣ



www.espa.gr

disease planning air travel: British Thoracic Society recommendations. *Thorax*. 2011; 66(1):1-30.

150. Edvardsen A, Akerø A, Hardie JA, Ryg M, Eagan TM, Skjønberg OH, Bakke PS. High prevalence of respiratory symptoms during air travel in patients with COPD. *Respir Med*. 2011; 105(1):50–6.

151. Nicholson AN, Cummin AR, Giangrande PL. The airline passenger: current medical issues. *Travel Med Infect Dis*. 2003; 1(2):94–102.

152. Monninkhof EM, van der Valk PD, van der Palen J, van Herwaarden CL, Partidge MR, Walters EH, Zielhuis GA. Self-management education for patients with chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*. 2007; (4):CD002990.

153. Effing T, Monninkhof EM, van der Valk PD, van der Palen J, van Herwaarden CL, Partidge MR, Walters EH, Zielhuis GA. Self-management education for patients with chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*. 2007; (4):CD002990.

154. Wood-Baker R, McGlone S, Venn A, Walters EH. Written action plans in chronic obstructive pulmonary disease increase appropriate treatment for acute exacerbations. *Respirology*. 2006; 11(5):619-26.

155. McGeoch GR, Willsman KJ, Dowson CA, Town GI, Frampton CM, McCartin FJ, Cook JM, Epton MJ. Self-management plans in the primary care of patients with chronic obstructive pulmonary disease. *Respirology*. 2006; 11(5):611-8.

156. Tabak C, Arts W, Ilja C, Smit-Henriette A, Heederik D, Krohmout D. Chronic Obstructive Pulmonary Disease and Intake of Catechins, Flavonols, and Flavones". *American Journal of Respiratory and Critical Care Medicine*. 2001; 164(1):61-4.

157. Grievink L, Smit H A, Ocké M C, van 't Veer P, Kromhout D. Dietary intake of antioxidant (pro)-vitamins, respiratory symptoms and pulmonary function: the MORGEN study. *Thorax*. 1998; 53(3):166-71.

158. Schols AM, Slangen J, Volovics L, Wouters EF. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. *American Journal of Respiratory Critical Care Medicine*. 1998; 157(6):1791-7.



ΕΥΡΩΠΑΪΚΗ ΕΝΩΣΗ



www.ygeia-pronoia.gr

Με την συγχρηματοδότηση
της Ελλάδας και της
Ευρωπαϊκής Ένωσης

2007-2013

Ε.Π.
ΔΙΟΙΚΗΤΙΚΗ
ΜΕΤΑΡΡΥΘΜΙΣΗ
ΜΕΛΕΤΗ



ΕΥΡΩΠΑΪΚΟ ΚΟΙΝΩΝΙΚΟ ΤΑΜΕΙΟ

www.espa.gr

159. Gorecka D, Gorzelak K, Sliwinski P, Tobiasz M, Zielinski J. Effect of long-term oxygen therapy on survival in patients with chronic obstructive pulmonary disease with moderate hypoxaemia. *Thorax*. 1997; 52:674-9.
160. Landbo C, Prescott E, Lange P, Vestbo J, Almdal TP. Prognostic value of nutritional status in chronic obstructive pulmonary disease. *American Journal of Critical Care Medicine*. 1999; 160(6):1856-61.
161. Prescott E, Almdal T, Mikkelsen KL, Tofteng CL, Vestbo J, Lange P. Prognostic value of weight change in chronic obstructive pulmonary disease: results from the Copenhagen City Heart Study. *Eur Respir J*. 2002; 20(3):539-44.
162. Lacasse Y, Wong E, Guyatt GH, King D, Cook DJ, Goldstein RS. Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease. *Lancet*. 1996; 348:1115-9.
163. COPD Working Group. Pulmonary rehabilitation for patients with chronic pulmonary disease (COPD): an evidence-based analysis. *Ont Health Technol Assess Ser*. 2012; 12(6):1-75.
164. Berry MJ, Rejeski WJ, Adair NE, Zaccaro D. Exercise rehabilitation and chronic obstructive pulmonary disease stage. *Am J Respir Crit Care Med*. 1999; 160(4):1248-53.
165. Griffiths TL, Phillips CJ, Davies S, Burr ML, Campbell IA. Cost effectiveness of an outpatient multidisciplinary pulmonary rehabilitation programme. *Thorax*. 2001; 56(10):779-84.
166. Kruis AL, Smidt N, Assendelft WJ, Gussekloo J, Boland MR, Rutten-van Mölken M, Chavannes NH. Integrated disease management interventions for patients with chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*. 2013; (10):CD009437.
167. Romieu I, Riojas-Rodriguez H, Marron-Mares AT, Schilman A, Perez-Padilla R, Masera O. Improved biomass stove intervention in rural Mexico: impact on the respiratory health of women. *Am J Respir Crit Care Med*. 2009; 180:649-56.



ΕΥΡΩΠΑΪΚΗ ΕΝΩΣΗ



ΥΠΟΥΡΓΕΙΟ ΥΓΕΙΑΣ

Με την συγχρηματοδότηση
της Ελλάδας και της
Ευρωπαϊκής Ένωσης



Ε.Π.
ΔΙΟΙΚΗΤΙΚΗ
ΜΕΤΑΡΡΥΘΜΙΣΗ
ΜΕΛΕΤΕΣ



ΕΥΡΩΠΑΪΚΟ ΚΟΙΝΩΝΙΚΟ ΤΑΜΕΙΟ

www.espa.gr

www.ygeia-pronoia.gr

168. Liu S, Zhou Y, Wang X, Lu J, Zheng J, Zhong N, Ran P. Biomass fuels are the probable risk factor for chronic obstructive pulmonary disease in rural South China. *Thorax*. 2007; 62:889-97.
169. Zhou Y, Hu G, Wang D, Wang S, Wang Y, Liu Z, Hu J, Shi Z, Peng G, Liu S, Lu J, Zheng J, Wang J, Zhong N, Ran P. Community based integrated intervention for prevention and management of chronic obstructive pulmonary disease (COPD) in Guangdong, China: cluster randomised controlled trial. *BMJ*. 2010; 341:c6387.
170. Wongsurakiat P, Maranetra KN, Wasi C, Kositanont U, Dejsomritrutai W, Charoenratanakul S. Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. *Chest*. 2004; 125:2011-20.
171. Nichol KL. The additive benefits of influenza and pneumococcal vaccinations during influenza seasons among elderly persons with chronic lung disease. *Vaccine*. 1999; 17(1):91-3.
172. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. *N Engl J Med*. 1994; 331:778-84.
173. Wongsurakiat P, Lertakyamanee J, Maranetra KN, Jongriratanakul S, Sangkaew S. Economic evaluation of influenza vaccination in Thai chronic obstructive pulmonary disease patients. *J Med Assoc Thai*. 2003; 86:497-508.
174. Centers for Disease Control and Prevention. Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices - United States, 2013-2014. *MMWR Recomm Rep*. 2013; 62(07):1-43.
175. Alfageme I, Vazquez R, Reyes N, Muñoz J, Fernández A, Hernandez M, Merino M, Perez J, Lima J. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. *Thorax*. 2006; 61(3):189-95.
176. Walters JA, Smith S, Poole P, Granger RH, Wood-Baker R. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. *Cochrane Database* 2010; (11):CD001390.



ΕΥΡΩΠΑΪΚΗ ΕΝΩΣΗ



www.ygeia-pronoia.gr

Με την συγχρηματοδότηση
της Ελλάδας και της
Ευρωπαϊκής Ένωσης

2007-2013

Ε.Π.
ΔΙΟΙΚΗΤΙΚΗ
ΜΕΤΑΡΡΥΘΜΙΣΗ
ΜΕΛΕΤΕΣ



www.espa.gr

177. Coakley AL. Helping patients to master correct inhaler techniques: Nursing role. British Journal of Nursing. 2001; 10(7):424-8.
178. Wright J, Brocklebank D, Ram F. Inhaler devices for the treatment of asthma and chronic obstructive airway disease (COPD). Quality and Safety in Healthcare. 2002; 11(4):376-382.
179. Cochrane MG, Bala MV, Downs KE, Mauskopf J, Ben Joseph, RH. Inhaled corticosteroids for asthma therapy: Patient compliance, devices and inhalation technique. Chest. 2000; 117(2):542-50.
180. Christensen EF, Nedergaard T, Dahl R. Long-term treatment of chronic bronchitis with positive expiratory pressure mask and chest physiotherapy. Chest. 1990; 97(3):645-50.
181. McLean S, Nurmatov U, Liu JLY, Pagliari C, Car J, Sheikh A. Telehealthcare for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2011; (7):CD007718.
182. Vitacca M, Bianchi L, Guerra A, Fracchia C, Spanevello A, Balbi B, Scalvini S. Tele-assistance in chronic respiratory failure patients: a randomised clinical trial. Eur Respir J. 2009; 33(2):411-8.



ΕΥΡΩΠΑΪΚΗ ΕΝΩΣΗ



ΥΠΟΥΡΓΕΙΟ ΥΓΕΙΑΣ

Με την συγχρηματοδότηση
της Ελλάδας και της
Ευρωπαϊκής Ένωσης



Ε.Π.
ΔΙΟΙΚΗΤΙΚΗ
ΜΕΤΑΡΡΥΘΜΙΣΗ
ΜΕΣΤΕΡΕΥΣΗ



ΕΣΠΑ
2007-2013
πρόγραμμα για την ανάπτυξη
ΕΥΡΩΠΑΪΚΟ ΚΟΙΝΩΝΙΚΟ ΤΑΜΕΙΟ

www.espa.gr

www.ygeia-pronoia.gr

"Αυτό το έγγραφο έχει παραχθεί για τις ανάγκες του έργου με τίτλο «Ανάπτυξη 13 Κατευθυντήριων Οδηγιών Γενικής Ιατρικής για τη διαχείριση των πιο συχνών νοσημάτων και καταστάσεων υγείας στην Πρωτοβάθμια Φροντίδα Υγείας» και αντιπροσωπεύει τις απόψεις των συντακτών του. Οι απόψεις αυτές δεν έχουν υιοθετηθεί ή εγκριθεί με οποιοδήποτε τρόπο από την Ειδική Υπηρεσία του τομέα Υγείας & Κοινωνικής Αλληλεγγύης και της Ευρωπαϊκής Επιτροπής και δεν πρέπει να εκλαμβάνονται ως θέσεις του Υπουργείου ή της Επιτροπής. Η Ειδική Υπηρεσία δεν εγγυάται την ακρίβεια των στοιχείων που περιλαμβάνονται στο παρόν έγγραφο, ούτε αποδέχεται την ευθύνη για οποιαδήποτε χρήση των πληροφοριών αυτών. "